S
Stanley C. Jordan
Researcher at Cedars-Sinai Medical Center
Publications - 368
Citations - 15362
Stanley C. Jordan is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 60, co-authored 344 publications receiving 13215 citations. Previous affiliations of Stanley C. Jordan include University of Oulu & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Ashley Vo,Marina Lukovsky,Mieko Toyoda,Jennifer Wang,Nancy L. Reinsmoen,Chih-Hung Lai,Alice Peng,Rafael Villicana,Stanley C. Jordan +8 more
TL;DR: Findings suggest that the combination of intravenous immune globulin and rituximab may prove effective as a desensitization regimen for patients awaiting a transplant from either a living donor or a deceased donor.
Journal ArticleDOI
National conference to assess antibody-mediated rejection in solid organ transplantation.
Steven K. Takemoto,Adriana Zeevi,Sandy Feng,Robert B. Colvin,Stanley C. Jordan,Jon A. Kobashigawa,Jerzy W. Kupiec-Weglinski,Arthur J. Matas,Robert A. Montgomery,Peter Nickerson,Jeffrey L. Platt,Hamid Rabb,Richard Thistlethwaite,Dolly B. Tyan,Francis L. Delmonico +14 more
TL;DR: The process of humoral rejection is multifaceted and has different manifestations in the various types of organ transplants.
Journal ArticleDOI
Update on the use of immunoglobulin in human disease: A review of evidence
Elena E. Perez,Jordan S. Orange,Francisco A. Bonilla,Javier Chinen,Ivan K. Chinn,Morna J. Dorsey,Yehia El-Gamal,Terry Harville,Elham Hossny,Bruce Mazer,Robert P. Nelson,Elizabeth Secord,Stanley C. Jordan,E. Richard Stiehm,Ashley Vo,Mark Ballow +15 more
TL;DR: This work provides an update of the evidence‐based guideline on immunoglobulin therapy, last published in 2006, and suggests that careful consideration of its indications and administration is warranted.
Journal ArticleDOI
Evaluation of Intravenous Immunoglobulin as an Agent to Lower Allosensitization and Improve Transplantation in Highly Sensitized Adult Patients with End-Stage Renal Disease: Report of the NIH IG02 Trial
Stanley C. Jordan,Stanley C. Jordan,Dolly B. Tyan,Don M. Stablein,Matthew McIntosh,Steve Rose,Ashley Vo,Mieko Toyoda,Connie L. Davis,Ron Shapiro,Deborah Adey,Dawn S. Milliner,Ralph J. Graff,Robert W. Steiner,Gaetano Ciancio,Shobah Sahney,Jimmy A. Light +16 more
TL;DR: It is concluded that IVIG is better than placebo in reducing anti-HLA antibody levels and improving transplantation rates in highly sensitized patients with ESRD awaiting kidney transplants.
Journal ArticleDOI
Cell-Free DNA and Active Rejection in Kidney Allografts
Roy D. Bloom,Jonathan S. Bromberg,Emilio D. Poggio,Suphamai Bunnapradist,Anthony Langone,Puneet Sood,Arthur J. Matas,Shikha Mehta,Roslyn B. Mannon,Asif Sharfuddin,Bernard Fischbach,Mohanram Narayanan,Stanley C. Jordan,Stanley C. Jordan,David J. Cohen,Matthew R. Weir,D. Hiller,Preethi Prasad,Robert Woodward,Marica Grskovic,John J. Sninsky,J. Yee,Daniel C. Brennan +22 more
TL;DR: Donor-derived cell-free DNA may be used to assess allograft rejection and injury; dd-cfDNA levels <1% reflect the absence of active rejection (T cell-mediated type ≥IB or ABMR) and levels >1% indicate a probability of active rejected.